Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
12'-O-(2-methoxyethyl) phosphorothioate antisense oligonucleotide targeting CD49D RNA----1件: 113 💬
22-CDA1件: Cladribine (2-CdA)1件: Cladribine 💬 1件: RRM1 💬 4件: Drug metabolism - other enzymes, Glutathione metabolism, Purine metabolism, Pyrimidine metabolism 💬1件: 13 💬
32-CDA, 2-chloro-2'-deoxy-ß-D-adenosine1件: Cladribine (2-CdA)1件: Cladribine 💬 1件: RRM1 💬 4件: Drug metabolism - other enzymes, Glutathione metabolism, Purine metabolism, Pyrimidine metabolism 💬1件: 13 💬
42-CDA, 2-chloro-2?-deoxy-ß-D-adenosine1件: Cladribine (2-CdA)1件: Cladribine 💬 1件: RRM1 💬 4件: Drug metabolism - other enzymes, Glutathione metabolism, Purine metabolism, Pyrimidine metabolism 💬1件: 13 💬
52-CDA, 2-chloro-2’-deoxy-ß-D-adenosine1件: Cladribine (2-CdA)1件: Cladribine 💬 1件: RRM1 💬 4件: Drug metabolism - other enzymes, Glutathione metabolism, Purine metabolism, Pyrimidine metabolism 💬1件: 13 💬
6Aavrh.10hfxn, serotype RH.10 adeno-associated virus (AAV) gene transfer vector expressing THE cdna coding FOR human FXN----1件: 18 💬
7Adeno-associated virus serotype 2/6 encoding human alpha-galactosidase A cdna----1件: 19 💬
8ALLO-ASC-CD----1件: 96 💬
9Amniotic fluid or placental CD117 stem cells----1件: 13 💬
10Anti CD19 CAR NK cells----1件: 46 💬
11Anti CD3 monoclonal antibody----1件: 97 💬
12ANTI-bcma/CD70-CAR-T cells----1件: 49 💬
13ANTI-CD19 CAR T cell therapy----4件: 49, 50, 51, 53 💬
14ANTI-CD19 CAR-NK cells----3件: 49, 51, 53 💬
15ANTI-CD19 CAR-T cells----2件: 51, 53 💬
16ANTI-CD19 UCAR-T cells----1件: 50 💬
17ANTI-CD19-CAR-T cells----3件: 49, 51, 53 💬
18ANTI-CD19-CD3E-CAR-T cells----3件: 49, 51, 53 💬
19ANTI-CD19/bcma CAR NK cells----1件: 66 💬
20ANTI-CD20 antibody----2件: 13, 64 💬
21ANTI-CD20 B cell depletion with truxima----1件: 49 💬
22ANTI-CD20 MAB----1件: 13 💬
23ANTI-CD20 monoclonal antibody----1件: 13 💬
24ANTI-CD20 MS treatment----1件: 13 💬
25ANTI-CD20 small modular immunopharmaceutical, WYE-400087----1件: 46 💬
26ANTI-CD25 humanized monoclonal antibody----1件: 13 💬
27ANTI-CD28DAB----3件: 49, 53, 160 💬
28ANTI-CD31件: Muromonab (Anti-CD3)1件: Muromonab-CD3 (Muromonab-CD3) 💬 3件: CD3D,
CD3E,
CD3G 💬 		11件: Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬1件: 96 💬
29ANTI-CD3 monoclonal antibody1件: Muromonab (Anti-CD3)1件: Muromonab-CD3 (Muromonab-CD3) 💬 3件: CD3D,
CD3E,
CD3G 💬 		11件: Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬2件: 96, 97 💬
30ANTI-CD38 antibody injection----2件: 61, 63 💬
31ANTI-CD38 monoclonal antibody----1件: 28 💬
32ANTI-CD40L1件: Toralizumab (Anti-CD40L)1件: Toralizumab 💬 1件: TNFSF5 💬 14件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, Lipid and atherosclerosis, Malaria, NF-kappa B signaling pathway, Primary immunodeficiency, Systemic lupus erythematosus, T cell receptor signaling pathway, Toxoplasmosis, Viral myocarditis 💬1件: 63 💬
33ANTI-CD40ldab----1件: 63 💬
34ANTI-CD45----2件: 65, 285 💬
35ANTI-CD52 monoclonal antibody----1件: 13 💬
36AP-CD/LD----1件: 6 💬
37Assigned interventions CD19/bcma CAR T-cells----3件: 49, 51, 53 💬
38Autologous CD34 positive cells transduced with A lentiviral vector containing human WAS gene----1件: 65 💬
39Autologous CD34+ cells transduced EX-vivo with THE pcclchimgp91/vsvg lentiviral vector----1件: 65 💬
40Autologous CD34+ cells transduced with A lentiviral vector containing THE human sgsh gene----1件: 19 💬
41Autologous CD34+ cells transduced with A lentiviral vector encoding THE arsa cdna----1件: 19 💬
42Autologous CD34+ cells transduced with lenti-D vector encoding ABCD1 cdna1件: Elivaldogene tavalentivec---1件: 20 💬
43Autologous CD34+ cells transduced with THE G1xcgd lentiviral vector----1件: 65 💬
44Autologous CD34+ cells transduced with THE lentiviral vector containing THE human wiskott aldrich SY----1件: 65 💬
45Autologous CD34+ cells transduced with wasp lentiviral vector----1件: 65 💬
46Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes FOR THE human wiskott aldrich syndrome (WAS) cdna sequence----1件: 65 💬
47Autologous CD34+ hscs transduced EX vivo with CD11B LV encoding human IDS tagged with apoeii----1件: 19 💬
48Autologous CD34+ hscs transduced EX vivo with EFS lentiviral vector encoding FOR THE human ADA gene----1件: 65 💬
49Autologous CD34+cells transduced with THE W1.6_hwasp_wpre (vsvg) lentiviral vector----1件: 65 💬
50Autologous CD34-selected peripheral blood stem cells transplant----1件: 96 💬
51Autologous CD4+T cells stimulated and expanded EX vivo BY A MOG peptide modified BY THE introduction OF A thioreductase motif into THE flanking residues OF THE T cell epitope----1件: 13 💬
52Autologous haematopoietic stem cells transduced with lentiviral vector lenti-D encoding THE human ABCD1 cdna1件: Elivaldogene tavalentivec---1件: 20 💬
53Autologous stemcell transplantation with CD (cluster OF differentiation) 34 selected stem cells----1件: 51 💬
54BCMA-CD19 CAR-T therapy----5件: 49, 51, 53, 56, 64 💬
55Bcma/CD19 CAR-T cells----2件: 49, 53 💬
56Blinded cdca 250 MG TID1件: Chenodeoxycholic acid (CDCA)1件: Chenodiol 💬 1件: NR1H4 💬 1件: Bile secretion 💬1件: 263 💬
57CD-4 guided therapy interruption----1件: 265 💬
58CD-C-food----1件: 96 💬
59CD-LD CR----1件: 6 💬
60CD-LD IR----1件: 6 💬
61CD19 CAR-T cell infusion----1件: 49 💬
62CD19 CAR-T cells----1件: 49 💬
63CD19 targeted CAR-T cells----3件: 50, 51, 53 💬
64CD19 universal CAR-?D T cells----1件: 49 💬
65CD19 universal CAR-T cells----1件: 49 💬
66CD19- bcma CAR-T cells----4件: 43, 49, 51, 53 💬
67CD19-bcma CAR-T cells infusion----3件: 49, 51, 53 💬
68CD19-bcma targeted CAR-T dose 1----1件: 11 💬
69CD19-bcma targeted CAR-T dose 2----1件: 11 💬
70CD19-CAR-DNT cells----2件: 49, 51 💬
71CD19-directed humanised afucosylated monoclonal antibody----1件: 11 💬
72CD19-targetd CAR-T----1件: 50 💬
73CD19/bcma CAR T-cells----2件: 16, 61 💬
74CD19/bcma CAR-T cell therapy----1件: 49 💬
75CD20/BCMA-directed CAR-T cells----3件: 11, 13, 49 💬
76CD3-depleted hematopoietic cell transplantation----1件: 60 💬
77CD3/CD19 depleted leukocytes----1件: 284 💬
78CD3/CD19 NEG allogeneic BMT----1件: 65 💬
79CD3/CD19 negative allogeneic hematopoietic stem cells----1件: 65 💬
80CD3/CD19 negative hematopoietic stem cells----1件: 85 💬
81CD34 selected autologous hematopoietic cells----1件: 51 💬
82CD34 selected haploidentical pbsct----1件: 285 💬
83CD34 stem cell selection therapy----3件: 60, 65, 284 💬
84CD34+ bone marrow stem cells intravitreal----1件: 90 💬
85CD34+ cell enriched stem cell graft----2件: 65, 285 💬
86CD34+ cells----1件: 285 💬
87CD34+ cells enriched with MNV-BLD----1件: 21 💬
88CD34+ enriched, T cell depleted donor stem cell product----1件: 326 💬
89CD34+ hscs transduced with THE lentivirus vector, VSV-G pseudotyped CL20-4I-EF1A-H?C-OPT----1件: 65 💬
90CD34+ peripheral blood stem cell reinfusion----1件: 49 💬
91CD34+ selected cells----1件: 285 💬
92CD34+cells----2件: 65, 285 💬
93CD34+SC----1件: 51 💬
94CD3±CD19 depleted hematopoietic stem cell transplantation----1件: 60 💬
95CD4-IGG----1件: 63 💬
96CD45RA depleted leukocytes----1件: 284 💬
97CD45RA-depleted DLI----1件: 60 💬
98CD62L- TEM----1件: 60 💬
99CD7 CAR T-cells----3件: 50, 96, 97 💬
100CD7 CAR-T cells injection----1件: 60 💬
101Cdca weight-based dose TID1件: Chenodeoxycholic acid (CDCA)1件: Chenodiol 💬 1件: NR1H4 💬 1件: Bile secretion 💬1件: 263 💬
102Cded (crohn'S disease exclusion diet) IN addition TO ANTI-TNF therapy----2件: 96, 97 💬
103Cded+dairy----1件: 96 💬
104Cded+PEN----1件: 96 💬
105Cdmard----1件: 46 💬
106Cdnf----1件: 6 💬
107CDP 6038 SC----1件: 46 💬
108CDP3194----1件: 49 💬
109CDP3231件: CDP323 (CDP323)---1件: 13 💬
110CDP6038----2件: 46, 96 💬
111CDP7657----1件: 49 💬
112CDP870----3件: 46, 96, 271 💬
113CDP870 100MG----1件: 46 💬
114CDP870 200MG----1件: 46 💬
115CDP870 400MG----1件: 46 💬
116CDP870 FAB'-PEG----1件: 46 💬
117CDX 6114----1件: 240 💬
118CDX-0159----1件: 98 💬
119CDX-11351件: CDX-1135 (CDX 1135)---1件: 222 💬
120CDZ173----2件: 53, 65 💬
121Cellule CD34+ autologhe trasdotte CON idua LV codificante PER IL cdna dell'ALFA-L-iduronidasi----1件: 19 💬
122Chimeric human/mouse ANTI-CD-20 monoclonal antibody----1件: 46 💬
123CHX A-dtpa ANTI-CD66 antibody----1件: 28 💬
124CHX-A-DTPA-ANTI-CD66----1件: 28 💬
125Clinimacs® TCR A/ß reagent KIT and clinimacs® CD19 system----3件: 19, 96, 222 💬
126CM-336 bcma/CD3 bispecific antibody----1件: 28 💬
127Combination OF A single dose ANTI-CD20 antibody and bortezomib----1件: 61 💬
128Companion diagnostic (CDX) testing----1件: 97 💬
129Cryopreserved autologous CD34+ cells transduced with A lentiviral vector containing human sgsh gene----1件: 19 💬
130Cryopreserved autologous CD34+ cells transduced with pcclchim-P47----1件: 65 💬
131Cryopreserved EFS-ADA LV transduced patient CD34+ cells----1件: 65 💬
132Cryopreserved G2scid lentiviral vector transduced patient CD34+ cells----1件: 65 💬
133Cytolytic CD4+ T cells----1件: 13 💬
134Cytoreductive regimen followed BY A CD34+E- selected allogeneic stem cell transplant----1件: 62 💬
135D-methylphenidate
(METADATE CD, METHYLPHENIDATE HYDROCHLORIDE CD)		----1件: 84 💬
136Depletion OF CD3/CD19 IN AN autologous stem cell transplant----2件: 49, 51 💬
137Diltiazem
(Dilt-CD, CARDIZEM CD, DILTIAZEM HCL CD)		1件: Diltiazem3件: Diltiazem hydrochloride (Dilt-CD, CARDIZEM CD, DILTIAZEM HCL CD),
Diltiazem malate ,
Diltiazem 💬 		4件: CACNA1C,
CACNA1D,
CACNA1F,
CACNA1S 💬 		37件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬3件: 51, 58, 88 💬
138Diltiazem hydrochloride
(Dilt-CD, CARDIZEM CD, DILTIAZEM HCL CD)		1件: Diltiazem3件: Diltiazem hydrochloride (Dilt-CD, CARDIZEM CD, DILTIAZEM HCL CD),
Diltiazem malate ,
Diltiazem 💬 		4件: CACNA1C,
CACNA1D,
CACNA1F,
CACNA1S 💬 		37件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86 💬
139Duodopa LD/CD 20/5 MG/ML2件: Carbidopa,
Levodopa		2件: Levodopa ,
Carbidopa 💬 		6件: DDC,
DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬 		17件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Hormone signaling, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬1件: 6 💬
140Engineering OF chimeric antigen receptors targeting CD19 IN allogeneic T cells----1件: 49 💬
141ER CD-LD----1件: 6 💬
142EX vivo culture and transduction OF THE patient'S autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4I-EF1alpha-hgammac-OPT vector----1件: 65 💬
143Expression OF CDKN2A /P16ink4A----1件: 46 💬
144FC- and CDR-modified humanised monoclonal antibody against C5----3件: 11, 62, 109 💬
145G1xcgd transduced CD34+ cells----1件: 65 💬
146GENE-transduced autologous CD34+ stem cells----1件: 65 💬
147GSK2018682 CD2 capsule----1件: 13 💬
148GSK2018682 CD3 micronised tablet----1件: 13 💬
149GSK2018682 CD3 NON-micronised tablet IN FED state----1件: 13 💬
150Human glucocerebrosidase cdna----1件: 19 💬
151Human IGG4 monoclonal antibody against CD40----1件: 46 💬
152Human monoclonal antibody directed against CD20 ON B-cells----1件: 46 💬
153Humanised ANTI-CD 20 antibody----1件: 46 💬
154Humanised ANTI-CD4 IGG1 monoclonal----1件: 46 💬
155Humanized recombinant IGG4 monoclonal antibody against CD-127----1件: 97 💬
156Humax-CD201件: Ofatumumab (HuMax-CD20)1件: Ofatumumab 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬2件: 13, 46 💬
157Humax-CD38----2件: 28, 63 💬
158Humax-CD38, 3003-005----1件: 28 💬
159Humax-CD41件: Zanolimumab (Humax-cd4)1件: Zanolimumab 💬 1件: CD4 💬 14件: Antigen processing and presentation, Cell adhesion molecules, Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral life cycle - HIV-1, Virion - Human immunodeficiency virus, Yersinia infection 💬1件: 46 💬
160Indium 111-radiolabelled ANTI-CD661件: Indium---1件: 28 💬
161Indium­ 111 ­labelled anti­-CD661件: Indium---1件: 28 💬
162Inebilizumab
(Inebilizumab-cdon)		1件: Inebilizumab1件: Inebilizumab (Inebilizumab-cdon) 💬 1件: CD19 💬 5件: B cell receptor signaling pathway, Epstein-Barr virus infection, Hematopoietic cell lineage, PI3K-Akt signaling pathway, Primary immunodeficiency 💬6件: 11, 13, 46, 49, 51, 300 💬
163Infusion OF autologous EFS-ADA LV CD34+ cells----1件: 65 💬
164Intravitreal autologous CD34+ cells----1件: 90 💬
165IPX203 ER CD-LD----1件: 6 💬
166IR CD-LD----1件: 6 💬
167IR CD-LD (carbidopa-levodopa) tablets2件: Carbidopa,
Levodopa		2件: Levodopa ,
Carbidopa 💬 		6件: DDC,
DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬 		17件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Hormone signaling, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬1件: 6 💬
168IR LD / CD----1件: 6 💬
169IR LD/CD----1件: 6 💬
170KYV-101 ANTI-CD19 CAR-T cell therapy----1件: 13 💬
171LD/CD----1件: 6 💬
172LD/CD SC solution----1件: 6 💬
173Lentiviral vector transduced CD34+ cells----1件: 65 💬
174Metabolically armed CD19 CAR-T cells----1件: 49 💬
175Methylphenidate
(METADATE CD, METHYLPHENIDATE HYDROCHLORIDE CD)		1件: Methylphenidate2件: Methylphenidate hydrochloride (METADATE CD, METHYLPHENIDATE HYDROCHLORIDE CD),
Methylphenidate 💬 		2件: SLC6A2,
SLC6A3 💬 		8件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Neuroactive ligand signaling, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬5件: 6, 13, 34, 84, 113 💬
176Methylphenidate 10MG tablets
(METADATE CD, METHYLPHENIDATE HYDROCHLORIDE CD)		1件: Methylphenidate2件: Methylphenidate hydrochloride (METADATE CD, METHYLPHENIDATE HYDROCHLORIDE CD),
Methylphenidate 💬 		2件: SLC6A2,
SLC6A3 💬 		8件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Neuroactive ligand signaling, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬1件: 84 💬
177Methylphenidate hydrochloride
(METADATE CD, METHYLPHENIDATE HYDROCHLORIDE CD)		1件: Methylphenidate2件: Methylphenidate hydrochloride (METADATE CD, METHYLPHENIDATE HYDROCHLORIDE CD),
Methylphenidate 💬 		2件: SLC6A2,
SLC6A3 💬 		8件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Neuroactive ligand signaling, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬2件: 6, 13 💬
178Methylphenidate modified release
(METADATE CD, METHYLPHENIDATE HYDROCHLORIDE CD)		1件: Methylphenidate2件: Methylphenidate hydrochloride (METADATE CD, METHYLPHENIDATE HYDROCHLORIDE CD),
Methylphenidate 💬 		2件: SLC6A2,
SLC6A3 💬 		8件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Neuroactive ligand signaling, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬1件: 13 💬
179Methylphenidate modified release 20 MG
(METADATE CD, METHYLPHENIDATE HYDROCHLORIDE CD)		1件: Methylphenidate2件: Methylphenidate hydrochloride (METADATE CD, METHYLPHENIDATE HYDROCHLORIDE CD),
Methylphenidate 💬 		2件: SLC6A2,
SLC6A3 💬 		8件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Neuroactive ligand signaling, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬1件: 13 💬
180Methylphenidate modified release 30 MG
(METADATE CD, METHYLPHENIDATE HYDROCHLORIDE CD)		1件: Methylphenidate2件: Methylphenidate hydrochloride (METADATE CD, METHYLPHENIDATE HYDROCHLORIDE CD),
Methylphenidate 💬 		2件: SLC6A2,
SLC6A3 💬 		8件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Neuroactive ligand signaling, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬1件: 13 💬
181Methylphenidate modified release 40 MG
(METADATE CD, METHYLPHENIDATE HYDROCHLORIDE CD)		1件: Methylphenidate2件: Methylphenidate hydrochloride (METADATE CD, METHYLPHENIDATE HYDROCHLORIDE CD),
Methylphenidate 💬 		2件: SLC6A2,
SLC6A3 💬 		8件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Neuroactive ligand signaling, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬1件: 13 💬
182Methylphenidate oral solution
(METADATE CD, METHYLPHENIDATE HYDROCHLORIDE CD)		1件: Methylphenidate2件: Methylphenidate hydrochloride (METADATE CD, METHYLPHENIDATE HYDROCHLORIDE CD),
Methylphenidate 💬 		2件: SLC6A2,
SLC6A3 💬 		8件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Neuroactive ligand signaling, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬1件: 206 💬
183Methylphenidate, fluoxetin, risperidone
(METADATE CD, METHYLPHENIDATE HYDROCHLORIDE CD)		1件: Methylphenidate2件: Methylphenidate hydrochloride (METADATE CD, METHYLPHENIDATE HYDROCHLORIDE CD),
Methylphenidate 💬 		2件: SLC6A2,
SLC6A3 💬 		8件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Neuroactive ligand signaling, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬2件: 179, 206 💬
184Miltenyi CD34 reagent system----1件: 60 💬
185Miltenyi clinimacs(R) CD34 reagent system----1件: 60 💬
186Minibody against CD8 conjugated TO desferrioxamine labeled with zirconium ZR 89----1件: 51 💬
187MUNC-CD34----1件: 65 💬
188Muromonab-CD31件: Muromonab (Anti-CD3)1件: Muromonab-CD3 (Muromonab-CD3) 💬 3件: CD3D,
CD3E,
CD3G 💬 		11件: Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬1件: 60 💬
189ND0612 (levodopa/carbidopa solution) + morning oral IR-LD/CD1件: Levodopa1件: Levodopa 💬 5件: DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬 		13件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Hormone signaling, Morphine addiction, Neuroactive ligand signaling, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6 💬
190OPEN-label cdca 250 MG TID1件: Chenodeoxycholic acid (CDCA)1件: Chenodiol 💬 1件: NR1H4 💬 1件: Bile secretion 💬1件: 263 💬
191Oral IR-LD/CD----1件: 6 💬
192P-CD19cd20-ALLO1 cells----1件: 49 💬
193Pcclchimgp91S lentiviral vector transduced CD34+ cells infusion----1件: 65 💬
194Phagocyte oxidase subunit transduced CD34 hematopoietic stem cells----1件: 65 💬
195Phase1 : cded/modulen™IBD® + maintenance therapy----1件: 96 💬
196Plerixafor mobilization OF autologous CD117 stem cells1件: Plerixafor1件: Plerixafor 💬 1件: CXCR4 💬 14件: Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral life cycle - HIV-1, Viral protein interaction with cytokine and cytokine receptor, Virion - Human immunodeficiency virus 💬1件: 299 💬
197Recombinant adeno-associated virus 2/6 vector encoding THE cdna FOR human alpha galactosidase A----1件: 19 💬
198Recombinant humanized ANTI-CD20 monoclonal antibody----1件: 13 💬
199Repair OF CDH W/alloderm----1件: 294 💬
200Repair OF CDH W/SIS gold----1件: 294 💬
201Rescue medication cdca 250 MG TID1件: Chenodeoxycholic acid (CDCA)1件: Chenodiol 💬 1件: NR1H4 💬 1件: Bile secretion 💬1件: 263 💬
202Retroviral SF71-GP91phox transduced CD34+ cells----1件: 65 💬
203Routine treatment OF CD----1件: 96 💬
204Semi continuous intra-oral administration OF LD/CD----1件: 6 💬
205Single infusion OF autologous CD34+ cells transduced with THE SELF-inactivating (SIN) gammaretroviral vector PSRS11.EFS.IL2RG.PRE----1件: 65 💬
206Standard LD/CD----1件: 6 💬
207Suspension OF autologous CD34+cells transduced with THE G1xcgd viral vector----1件: 65 💬
208T cell injection targeting CD19 chimeric antigen receptor----6件: 46, 49, 51, 53, 93, 300 💬
209T cell injection targeting CD7 chimeric antigen receptor----1件: 51 💬
210T cells transduced with chimeric antigen receptor ANTI-CD19----1件: 49 💬
211T-cell depleted & CD34+select/W/stemcell enriched product----1件: 65 💬
212TL011, anti CD20, FOR THE treatment OF rheumatoid arthritis----1件: 46 💬
213TPO-RAS combining ANTI-CD 20 monoclonal antibody----1件: 63 💬
214Transduced CD34+ cells----1件: 285 💬
215Transduced CD34+ hematopoietic stem cell----2件: 19, 20 💬
216Umbilical cord blood CD19-bcma CAR-T cells infusion----2件: 51, 53 💬
217Universal allogeneic ANTI-CD19/bcma CAR T-cells----1件: 61 💬
218Universal BCMA-CD19 cart----1件: 13 💬
219Universal CD19 CAR-T----2件: 11, 13 💬
220Yttrium-90 radiolabelled ANTI-CD66 antibody1件: Yttrium Y-90---1件: 28 💬
221Yttrium­90 radiolabelled anti­CD66----1件: 28 💬